PACE launches new funding for antimicrobial drug development
PACE, one of the UK’s largest public-private initiatives targeting early-stage antimicrobial drug and diagnostic development, has launched its third round of funding to support innovative projects.
The initiative has announced £6 million ($8 million) in funding for antibacterial treatment innovations, aiming to tackle resistant bacterial infections and addressing a gap in the current drug development pipeline.
According to the World Health Organization (WHO), over 80% of recently approved bacterial antimicrobial agents show similarities to existing drug classes, meaning their potential is limited as resistance mechanisms to these classes already exist. Without significant action and pipeline diversification, it is expected that, by 2050, bacterial AMR will be associated with more than eight million deaths per year and could cost the world $100 trillion.
The PACE initiative is looking to invest in innovative therapeutics to tackle bacterial infections with the highest AMR burden and most unmet need, as classified by the WHO. These include lower respiratory tract infections, urinary tract infections and bloodstream infections. AMR is making these infections increasingly harder to treat, often leading to unresolved or recurrent infections and an increased risk of sepsis, which can be fatal.
Urgent need for new antimicrobial drugs
The funding announced by PACE is also part of a broader £30 million ($40 million) investment, a collaboration between Innovate UK, LifeArc, and Medicines Discovery Catapult, to accelerate solutions for global AMR challenges. The latest funding round will provide up to £6 million ($8 million) to support up to eight promising early-stage, antibacterial therapeutics and will prioritise those that work in novel ways, target new mechanisms, and have the potential to treat infections caused by multidrug-resistant bacteria.
“Developing new antimicrobial drugs is hugely complex and challenging”, said Dr Beverly Isherwood, PACE Programme Director. “Through PACE, we’re offering vital funding and collaborative support to innovators working to tackle AMR, helping them move promising ideas toward the clinic and to the patients who urgently need them.”
“This latest funding round builds on our existing portfolio and the appetite we saw from the AMR community in our previous funding rounds. It reflects our commitment to support the most innovative global research in AMR, and we’re excited that we can now support even more pioneering projects that have the potential to save lives and protect future generations from drug-resistant infections.”
Bruno Quinney, Content Team, DDW
